Personalized T cell-mediated cancer immunotherapy: progress and challenges
TLDR
Progress toward personalizing T cell-mediated immunotherapy for cancer as well as challenges going forward are discussed.About:
This article is published in Current Opinion in Biotechnology.The article was published on 2017-12-01 and is currently open access. It has received 80 citations till now. The article focuses on the topics: Cancer immunotherapy & Immunotherapy.read more
Citations
More filters
Journal ArticleDOI
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Daniel K. Wells,Marit M. van Buuren,Kristen K. Dang,Vanessa M. Hubbard-Lucey,Kathleen C. F. Sheehan,Katie M. Campbell,Andrew Lamb,Jeffrey P. Ward,John Sidney,Ana Belen Blazquez,Andrew J. Rech,Jesse M. Zaretsky,Begonya Comin-Anduix,Alphonsus H. C. Ng,William Chour,Thomas Yu,Hira Rizvi,Jia M. Chen,Patrice Manning,Gabriela Steiner,Xengie Doan,Aly A. Khan,Amit A. Lugade,Ana M. Mijalkovic Lazic,Angela Frentzen,Arbel D. Tadmor,Ariella Sasson,Arjun A. Rao,Baikang Pei,Barbara Schrörs,Beata Berent-Maoz,Beatriz M. Carreno,Bin Song,Bjoern Peters,Bo Li,Brandon W. Higgs,Brian Stevenson,Christian Iseli,Christopher A. Miller,Christopher A. Morehouse,Cornelis J. M. Melief,Cristina Puig-Saus,Daphne van Beek,David Balli,David Gfeller,David Haussler,Dirk Jäger,Eduardo Cortes,Ekaterina Esaulova,Elham Sherafat,Francisco Arcila,Gabor Bartha,Geng Liu,George Coukos,Guilhem Richard,Han Chang,Han Si,Inka Zörnig,Ioannis Xenarios,Ion I. Mandoiu,Irsan Kooi,James P. Conway,Jan H. Kessler,Jason A. Greenbaum,Jason Perera,Jason Harris,Jasreet Hundal,Jennifer M. Shelton,Jianmin Wang,Jiaqian Wang,Joel Greshock,Jonathon Blake,Joseph D. Szustakowski,Julia Kodysh,Juliet Forman,Lei Wei,Leo J. Lee,Lorenzo F. Fanchi,Maarten Slagter,Maren Lang,Markus Mueller,Martin Löwer,Mathias Vormehr,Maxim N. Artyomov,Michael A. Kuziora,Michael F. Princiotta,Michal Bassani-Sternberg,Mignonette H. Macabali,Milica R. Kojicic,Naibo Yang,Nevena M. Ilic Raicevic,Nicolas Guex,Nicolas Robine,Niels Halama,Nikola M. Skundric,Ognjen Milicevic,Pascal Gellert,Patrick Jongeneel,Pornpimol Charoentong,Pramod K. Srivastava,Prateek Tanden,Priyanka Shah,Qiang Hu,Ravi Gupta,Richard Chen,Robert A. Petit,Robert Ziman,Rolf Hilker,Sachet A. Shukla,Sahar Al Seesi,Sean Michael Boyle,Si Qiu,Siranush Sarkizova,Sofie R. Salama,Song Liu,Song Wu,Sriram Sridhar,Steven L. C. Ketelaars,Suchit Jhunjhunwala,Tatiana Shcheglova,Thierry Schuepbach,Todd Creasy,Veliborka Josipovic,Vladimir B. Kovacevic,Weixuan Fu,Willem-Jan Krebber,Yi-Hsiang Hsu,Yinong Sebastian,Zeynep Kosaloglu Yalcin,Zhiqin Huang,Taha Merghoub,Taha Merghoub,Justin Guinney,Justin Guinney,Adam Kolom,Cheryl Selinsky,Antoni Ribas,Antoni Ribas,Matthew D. Hellmann,Nir Hacohen,Nir Hacohen,Alessandro Sette,Alessandro Sette,James R. Heath,Nina Bhardwaj,Fred Ramsdell,Robert D. Schreiber,Ton N. Schumacher,Pia Kvistborg,Nadine Defranoux +149 more
TL;DR: A model of tumor epitope immunogenicity was developed that filtered out 98% of non-immunogenic peptides with a precision above 0.70 and was validated in an independent cohort of 310 epitopes prioritized from tumor sequencing data and assessed for T cell binding.
Journal ArticleDOI
Programming CAR-T cells to kill cancer.
TL;DR: Major advances in the engineering of next-generation CAR-T therapies for haematologic cancers and solid cancers are surveyed, with particular emphasis on strategies for the control of CAR specificity and activity and on approaches for improvingCAR-T-cell persistence and overcoming immunosuppression.
Journal ArticleDOI
Alternative mRNA splicing in cancer immunotherapy
TL;DR: The promise of analysing mRNA processing events in cancer cells, with an emphasis on mRNA splicing, for the identification of potential new targets for cancer immunotherapy is discussed.
Journal ArticleDOI
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Jun Ishihara,Ako Ishihara,Koichi Sasaki,Steve S. Lee,John-Michael Williford,Mariko Yasui,Hiroyuki Abe,Lambert Potin,Lambert Potin,Peyman Hosseinchi,Kazuto Fukunaga,Michal M. Raczy,Laura T. Gray,Aslan Mansurov,Kiyomitsu Katsumata,Masashi Fukayama,Stephen J. Kron,Melody A. Swartz,Jeffrey A. Hubbell +18 more
TL;DR: The A3 domain of VWF can be used to improve safety and efficacy of systemically administered tumor drugs with high translational promise and it is shown that intravenously administered CBD protein accumulated mainly in tumors.
Journal ArticleDOI
TCR signal strength controls the differentiation of CD4 + effector and memory T cells.
TL;DR: It is concluded that strong TCR signals during early T cell activation favor terminal TH1 differentiation over long-term TH1 and T follicular helper cell memory responses.
References
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov,Serena Nik-Zainal,Serena Nik-Zainal,David C. Wedge,Samuel Aparicio,Sam Behjati,Sam Behjati,Andrew V. Biankin,Graham R. Bignell,Niccolo Bolli,Niccolo Bolli,Åke Borg,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Sandrine Boyault,Birgit Burkhardt,Adam Butler,Carlos Caldas,Helen Davies,Christine Desmedt,Roland Eils,Jorunn E. Eyfjord,John A. Foekens,Mel Greaves,Fumie Hosoda,Barbara Hutter,Tomislav Ilicic,Sandrine Imbeaud,Sandrine Imbeaud,Marcin Imielinsk,Natalie Jäger,David T. W. Jones,David T. Jones,Stian Knappskog,Stian Knappskog,Marcel Kool,Sunil R. Lakhani,Carlos López-Otín,Sancha Martin,Nikhil C. Munshi,Nikhil C. Munshi,Hiromi Nakamura,Paul A. Northcott,Marina Pajic,Elli Papaemmanuil,Angelo Paradiso,John V. Pearson,Xose S. Puente,Keiran Raine,Manasa Ramakrishna,Andrea L. Richardson,Andrea L. Richardson,Julia Richter,Philip Rosenstiel,Matthias Schlesner,Ton N. Schumacher,Paul N. Span,Jon W. Teague,Yasushi Totoki,Andrew Tutt,Rafael Valdés-Mas,Marit M. van Buuren,Laura van ’t Veer,Anne Vincent-Salomon,Nicola Waddell,Lucy R. Yates,Icgc PedBrain,Jessica Zucman-Rossi,Jessica Zucman-Rossi,P. Andrew Futreal,Ultan McDermott,Peter Lichter,Matthew Meyerson,Matthew Meyerson,Sean M. Grimmond,Reiner Siebert,Elias Campo,Tatsuhiro Shibata,Stefan M. Pfister,Stefan M. Pfister,Peter J. Campbell,Peter J. Campbell,Peter J. Campbell,Michael R. Stratton,Michael R. Stratton +84 more
TL;DR: It is shown that hypermutation localized to small genomic regions, ‘kataegis’, is found in many cancer types, and this results reveal the diversity of mutational processes underlying the development of cancer.
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi,Naiyer A. Rizvi,Matthew D. Hellmann,Matthew D. Hellmann,Alexandra Snyder,Alexandra Snyder,Pia Kvistborg,Vladimir Makarov,Jonathan J. Havel,William Lee,Jianda Yuan,Phillip Wong,Teresa S. Ho,Martin L. Miller,Natasha Rekhtman,Andre L. Moreira,Fawzia Ibrahim,Cameron Bruggeman,Billel Gasmi,Roberta Zappasodi,Yuka Maeda,Chris Sander,Edward B. Garon,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Ton N. Schumacher,Timothy A. Chan,Timothy A. Chan +28 more
TL;DR: Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.
Related Papers (5)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott,Zhuting Hu,Derin B. Keskin,Derin B. Keskin,Sachet A. Shukla,Sachet A. Shukla,Jing Sun,David J. Bozym,Wandi Zhang,Adrienne M. Luoma,Anita Giobbie-Hurder,Lauren Peter,Christina Chen,Oriol Olive,Todd A. Carter,Shuqiang Li,David J. Lieb,Thomas Eisenhaure,Evisa Gjini,Jonathan Stevens,William J. Lane,Indu Javeri,Kaliappanadar Nellaiappan,Andres M. Salazar,Heather Daley,Michael S. Seaman,Elizabeth I. Buchbinder,Elizabeth I. Buchbinder,Charles H. Yoon,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Scott J. Rodig,Scott J. Rodig,Dan H. Barouch,Dan H. Barouch,Dan H. Barouch,Jon C. Aster,Jon C. Aster,Gad Getz,Gad Getz,Kai W. Wucherpfennig,Donna Neuberg,Jerome Ritz,Jerome Ritz,Eric S. Lander,Eric S. Lander,Edward F. Fritsch,Edward F. Fritsch,Nir Hacohen,Nir Hacohen,Catherine J. Wu +51 more
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin,Evelyna Derhovanessian,Matthias Miller,Björn-Philipp Kloke,Petra Simon,Martin Löwer,Valesca Bukur,Arbel D. Tadmor,Ulrich Luxemburger,Barbara Schrörs,Tana Omokoko,Mathias Vormehr,Christian Albrecht,Anna Paruzynski,Andreas Kuhn,Janina Buck,Sandra Heesch,Katharina H Schreeb,Felicitas Müller,Inga Ortseifer,Isabel Vogler,Eva Godehardt,Sebastian Attig,Richard Rae,Andrea Breitkreuz,Claudia Tolliver,Martin Suchan,Goran Martic,Alexander Hohberger,Patrick Sorn,Jan Diekmann,Janko Ciesla,Olga Waksmann,Alexandra-Kemmer Brück,Meike Witt,Martina Zillgen,Andrée Rothermel,Barbara Kasemann,David Langer,Stefanie Bolte,Mustafa Diken,Sebastian Kreiter,Romina Nemecek,Christoffer Gebhardt,Christoffer Gebhardt,Stephan Grabbe,Christoph Höller,Jochen Utikal,Jochen Utikal,Christoph Huber,Carmen Loquai,Özlem Türeci +51 more